We are live on ! Find out more
VRCA icon

Verrica Pharmaceuticals

74 hedge funds and large institutions have $13M invested in Verrica Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 30 increasing their positions, 10 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 10

0.1% less ownership

Funds ownership: 3.32%3.21% (-0.1%)

9% less funds holding

Funds holding: 8174 (-7)

38% less capital invested

Capital invested by funds: $21M → $13M (-$7.95M)

44% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 16

Holders
74
Holders Change
-7
Holders Change %
-8.64%
% of All Funds
0.99%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
9
Increased
30
Reduced
10
Closed
16
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Qube Research & Technologies (QRT)
76
Qube Research & Technologies (QRT)
United Kingdom
-$24.7K -3,526 Closed
PI
77
PFG Investments
New York
-$19.5K -2,784 Closed
Jane Street
78
Jane Street
New York
-$16.9K -2,420 Closed
Citadel Advisors
79
Citadel Advisors
Florida
-$14.2K -2,029 Closed
VPIM
80
Vanguard Personalized Indexing Management
California
-$12.6K -1,807 Closed
EGM
81
Engineers Gate Manager
New York
-$10.8K -1,538 Closed
VF
82
Virtu Financial
New York
-$9K -1,305 Closed
M&T Bank
83
M&T Bank
New York
-$7.58K -1,083 Closed
GSC
84
Ground Swell Capital
South Carolina
-$7.37K -1,053 Closed
Simplex Trading
85
Simplex Trading
Illinois
-$3.73K -576 -79%
Nisa Investment Advisors
86
Nisa Investment Advisors
Missouri
-$235 -34 Closed
CAS
87
Coppell Advisory Solutions
Texas
-$140 -20 Closed
CT
88
Coastline Trust
Rhode Island
-$42 -6 Closed
C
89
Covestor
United Kingdom
+$356 +55 New

VRCA Hedge Fund Activity: Q1 2025 in Review

74 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Verrica Pharmaceuticals (VRCA) for Q1 2025, worth a combined $13M — down 38% from $21M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of VRCA and 9 opened new positions — a net loss of 7 holders — while 10 trimmed existing stakes and 30 added.

The largest buyer was Caligan Partners, adding an estimated $1.01M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $2.27M sold.

  • 74 institutional investors held Verrica Pharmaceuticals (VRCA) as of Q1 2025, down from 81 in Q4 2024.
  • Funds reported $13M of Verrica Pharmaceuticals stock for Q1 2025, down 38% quarter-over-quarter.
  • 9 funds opened new Verrica Pharmaceuticals positions in Q1 2025 and 16 closed out, a net change of -7 holders.
  • The largest Verrica Pharmaceuticals buyer in Q1 2025 was Caligan Partners, an estimated $1.01M added.
  • The largest Verrica Pharmaceuticals seller in Q1 2025 was Perceptive Advisors, an estimated $2.27M sold.

Based on aggregated 13F filings for Q1 2025.